Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO2109 and Toripalimab in Resected NSCLC
NCT07683832Phase 1Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2028
01
Overview
Phase 1, open-label, single-arm trial of ABO2109 in non-small cell lung cancer (NSCLC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Dose-Limiting Toxicity at 21 days, Treatment-Emergent Adverse Events and 2 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
ABO2109
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07683832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07683832.